Heparin to Prevent Blood Clots in Cancer Patients
Author Information
Author(s): Haas Sylvia, Schellong Sebastian M, Tebbe Ulrich, Gerlach Horst-Eberhard, Bauersachs Rupert, Melzer Nima, Abletshauser Claudia, Sieder Christian, Bramlage Peter, Riess Hanno
Primary Institution: Institut für Experimentelle Onkologie und Therapieforschung, Technische Universität München, Germany
Hypothesis
Does heparin-based prophylaxis reduce venous thromboembolic events and death in patients with cancer?
Conclusion
Certoparin and UFH were equally effective and safe in preventing bleeding complications in cancer patients.
Supporting Evidence
- Thromboembolic events in cancer patients occurred at 4.50% with certoparin and 6.03% with UFH.
- Major bleeding was comparable between treatment groups.
- Serious adverse events were more common in patients with cancer.
Takeaway
This study looked at how well two types of blood thinners work to prevent blood clots in cancer patients. Both worked similarly well.
Methodology
A post-hoc analysis of the CERTIFY trial comparing VTE rates and bleeding complications in cancer patients receiving certoparin or UFH.
Potential Biases
Differences in VTE risk between different cancer types were not sufficiently captured.
Limitations
The subgroup of patients with cancer was small compared to the overall sample size, limiting the power of the analysis.
Participant Demographics
Patients were aged ≥70 years, with 274 having cancer and 2,965 without cancer.
Statistical Information
P-Value
0.6078
Confidence Interval
95% CI 0.23-2.39
Statistical Significance
p=0.6078
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website